Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile?
A controlled randomised trial large enough to assess the value of anticoagulating stroke patients in atrial fibrillation would be difficult to conduct in the UK and the results would be applicable to only a small proportion of stroke patients. It would be more worthwhile to organise a trial that als...
Asıl Yazarlar: | Sandercock, P, Warlow, C, Bamford, J, Peto, R, Starkey, I |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
1986
|
Benzer Materyaller
-
Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
Yazar:: Turpie AGG
Baskı/Yayın Bilgisi: (2014-03-01) -
A new era of anticoagulant therapy in the prevention of stroke in non-rheumatic atrial fibrillation
Yazar:: Andrei Viktorovich Fonyakin, ve diğerleri
Baskı/Yayın Bilgisi: (2012-09-01) -
Adherence to oral anticoagulation in ischemic stroke patients with atrial fibrillation
Yazar:: Paula Tiili, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01) -
Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation
Yazar:: Tommaso Sacquegna, ve diğerleri
Baskı/Yayın Bilgisi: (2015-12-01) -
Prevalence of oral anticoagulation in atrial fibrillation
Yazar:: Eduardo Bartholomay, ve diğerleri
Baskı/Yayın Bilgisi: (2014-09-01)